Sai Parenteral's IPO

The price band is ₹392 per share with a lot size of 38 shares. Minimum investment: ₹14896.

Sai Parenteral’s Limited is a pharmaceutical formulations company engaged in the research, development, and manufacturing of pharmaceutical products. The company operates in two main segments: branded generic formulations and contract development and manufacturing organisation (CDMO) services for domestic and international markets. Its product portfolio covers multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins and supplements, analgesics, and dermatology. The company manufactures products in several dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenterals supplies its branded generic formulations to customers, including government agencies, pharmaceutical companies, hospitals, and distributors in India, and also exports products to markets such as Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company operates five manufacturing facilities in India, four of which are located in Hyderabad, Telangana, while another facility owned by its subsidiary Revat Laboratories is located in Ongole, Andhra Pradesh. These facilities manufacture pharmaceutical formulations in compliance with applicable regulatory standards.

Review the IPO's fundamentals, financials, and market conditions carefully. Always do your own research before investing.

Sai Parenteral's was founded by Mr Anil Kumar Karusala in 2001.